Ebola Vaccines and Antivirals: What Lies Ahead?
There are rapidly accelerating efforts underway by industry, governments, NGOS, international organizations, and foundations to bring forward Ebola vaccines and antivirals. There have been promising early returns, amidst considerable unknowns and acute pressures to find safe, effective, and affordable new technological tools. Ambitious field trials are set to begin in the new year in West Africa. Hear what lies ahead from those on the front lines:
Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Disease (NIAID)
Dr. Moncef Slaoui, Member of the GSK Board of Directors and the Corporate Executive Team
Dr. Johan Van Hoof, Global Therapeutic Area Head, Infectious Diseases and Vaccines, Janssen Research & Development, LLC
Mr. Rohit Malpani, Director of Policy and Analysis, Medecins Sans Frontieres Access Campaign
Dr. Julie Gerberding, President, Merck Vaccines
Dr. J. Stephen Morrison, Senior Vice President and Director of the CSIS Global Health Policy Center will moderate.
